Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of LAM561 with Temozolomide in Glioblastoma
NCT03867123Phase 1Completed
- Sponsor
- Laminar Pharma
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 2-hydroxyoleic acid in glioblastoma (GBM) (2 arms), sponsored by Laminar Pharma. Primary endpoints: Safety and Tolerability of LAM561 at 12 weeks and Maximum Tolerated Dose at 12 months. Started Dec 2018; status: completed.
02
Drugs
2-hydroxyoleic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03867123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867123.